Dissertation Defense: Sara Maimouni
Candidate Name: Sara Maimouni
Major: Cell Biology
Advisor: Stephen Byers, Ph.D.
Title: RARRES1 Modulation of Tubulin Deglutamylation Regulates Metabolism and Cell Survival
One of the driving mechanisms of cancer progression is the reprogramming of metabolic pathways in intermediary metabolism. Cancers increase their energy expenditure by increasing ATP production for utilization in anabolic pathways to increase production of proteins, nucleic acids and lipids. The Warburg Effect, where cancer cells predominantly use aerobic glycolysis rather than oxidative phosphorylation to produce ATP, was long thought to be the main initiating pathway in increasing tumor burden. However, compelling new evidence shows that there exists metabolic heterogeneity among and within tumors. Mitochondrial respiration often plays a major role in tumor progression, as many different cancers contain a subpopulation of slow-cycling tumor-initiating cells that are multidrug-resistant and dependent on oxidative phosphorylation. These cells represent a target for cancer therapy. However, the identification of endogenous regulators of mitochondrial respiration is understudied. Depletion of (RARRES1) occurs in many cancers, including melanoma, colon, prostate and breast cancers. Interestingly, in cancers associated with fibrosis, such as triple negative breast cancer, pancreatic and hepatocellular carcinomas, RARRES1 is overexpressed. Its role in metabolism might explain the duality of this protein in cancer. Our data show that RARRES1 and its target CCP2 regulate mitochondrial bioenergetics and subsequently alter energy homeostasis by modulating the function of the mitochondrial voltage-dependent anion channel (VDAC). The changes in energy homeostasis rewire glucose for biosynthetic pathways, such as de novo lipogenesis, that drive the pathogenicity and survival of cancer. These data lay the foundation for metabo-therapy of the many tumor types that exhibit RARRES1 depletion or overexpression and may have the added benefit of targeting drug-resistant tumor-initiating cells.
Monday, August 20, 2018 at 2:00pm to 4:00pm
Medical and Dental Building, NE 201C
3900 Reservoir Road, N.W., Washington